iScience,
Journal Year:
2024,
Volume and Issue:
27(9), P. 110719 - 110719
Published: Aug. 13, 2024
Optical
imaging
technology
has
become
increasingly
recognized
for
its
utility
in
diagnosing
atherosclerosis
thanks
to
advantages
such
as
high
spatial
resolution,
rapid
data
acquisition,
lack
of
radiation
exposure,
cost-effectiveness,
minimal
invasiveness,
and
limited
side
effects.
However,
traditional
luminogens
employed
optical
diagnostics
are
often
troubled
by
aggregation-caused
quenching
(ACQ)
effect,
causing
diagnostic
errors
Chemical Science,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 1, 2025
This
review
provides
an
overview
of
activatable
peptide–AIEgen
conjugates
for
tumor
imaging,
with
emphasis
on
the
most
recent
breakthroughs
in
past
three
years
(from
2022
to
late
2024)
Frontiers in Bioengineering and Biotechnology,
Journal Year:
2024,
Volume and Issue:
12
Published: Sept. 2, 2024
Myocardial
ischemia-reperfusion
injury
(MIRI)
is
a
critical
issue
that
arises
when
restoring
blood
flow
after
an
ischemic
event
in
the
heart.
Excessive
reactive
oxygen
species
(ROS)
production
during
this
process
exacerbates
cellular
damage
and
impairs
cardiac
function.
Recent
therapeutic
strategies
have
focused
on
leveraging
ROS
microenvironment
to
design
targeted
drug
delivery
systems.
ROS-responsive
biomaterials
emerged
as
promising
candidates,
offering
enhanced
efficacy
with
reduced
systemic
adverse
effects.
This
review
examines
mechanisms
of
overproduction
myocardial
summarizes
significant
advancements
for
MIRI
treatment.
We
discuss
various
chemical
impart
sensitivity
these
materials,
emphasizing
ROS-induced
solubility
switches
degradation
mechanisms.
Additionally,
we
highlight
platforms,
such
nanoparticles
hydrogels,
their
unique
advantages
MIRI.
Preclinical
studies
demonstrating
materials
mitigating
animal
models
are
reviewed,
alongside
action
potential
clinical
implications.
also
address
challenges
future
prospects
translating
state
art
biomaterial-based
therapeutics
into
practice
improve
management
outcomes.
will
provide
valuable
insights
researchers
clinicians
working
novel
intervention.
MedComm,
Journal Year:
2024,
Volume and Issue:
5(8)
Published: July 20, 2024
Abstract
Nanomaterials
have
aroused
great
interests
in
drug
delivery
due
to
their
nanoscale
structure,
facile
modifiability,
and
multifunctional
physicochemical
properties.
Currently,
stimuli‐responsive
nanomaterials
that
can
respond
endogenous
or
exogenous
stimulus
display
strong
potentials
biomedical
applications.
In
comparison
with
conventional
nanomaterials,
improve
therapeutic
efficiency
reduce
the
toxicity
of
drugs
toward
normal
tissues
through
specific
targeting
on‐demand
release
at
pathological
sites.
this
review,
we
summarize
responsive
mechanism
a
variety
stimulus,
including
pH,
redox,
enzymes
within
microenvironment,
as
well
such
thermal
effect,
magnetic
field,
light,
ultrasound.
After
that,
applications
(e.g.,
delivery,
imaging,
theranostics)
diverse
array
common
diseases,
cardiovascular
cancer,
neurological
disorders,
inflammation,
bacterial
infection,
are
presented
discussed.
Finally,
remaining
challenges
outlooks
future
research
directions
for
also
We
hope
review
provide
valuable
guidance
developing
accelerate
diseases
diagnosis
treatment.
ACS Applied Materials & Interfaces,
Journal Year:
2024,
Volume and Issue:
16(35), P. 46578 - 46589
Published: Aug. 22, 2024
Atherosclerosis
(AS)
is
characterized
by
the
accumulation
of
lipids
within
walls
coronary
arteries,
leading
to
arterial
narrowing
and
hardening.
It
serves
as
primary
etiology
pathological
basis
for
cardiovascular
diseases
affecting
heart
brain.
However,
conventional
pharmacotherapy
constrained
inadequate
drug
delivery
pronounced
toxic
side
effects.
Moreover,
inefficacy
nanomedicine
systems
in
controlling
disease
progression
may
be
attributed
nonspecific
clearance
mononuclear
phagocyte
system.
Thus,
a
biomimetic
platform
spontaneously
enveloped
red
blood
cell
membrane
exploited
anti-atherosclerosis
applications,
offering
favorable
biocompatibility.
The
CLIKKPF
polypeptide
introduced
develop
encapsulated
nanotherapeutics
only
through
simple
coincubation.
Given
functional
modifications,
RBC@P-LVTNPs
beneficial
facilitate
target
atherosclerotic
lesion,
responding
precisely
ROS
accumulation,
thereby
accelerating
on-demand
release.
Both
vivo
vitro
results
also
confirm
significant
therapeutic
efficacy
biocompatibility
system,
thus
providing
promising
candidate
against
AS.
